Susceptibility to RPR 106,972, quinupristin/dalfopristin and erythromycin among recent clinical isolates of enterococci, staphylococci and streptococci from North American medical centres.
An orally administered streptogramin (RPR 106,972) and a parenteral streptogramin (quinupristin/dalfopristin) were evaluated against a collection of 2481 recent clinical isolates of gram-positive cocci. The isolates were gathered from ten North American medical centres during the winter months of 1996-1997. In spite of minor differences, both streptogramins had essentially identical spectra of activity which included many erythromycin-resistant isolates. Previously proposed interpretative criteria for quinupristin/dalfopristin disc diffusion susceptibility tests were confirmed.
Barry
A L
AL
The Clinical Microbiology Institute, Wilsonville, OR 97070, USA. cmi@hevanet.com
Fuchs
P C
PC
Brown
S D
SD
D000046:Academic Medical Centers; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D004352:Drug Resistance, Microbial; D016983:Enterococcus / Q000187:drug effects; D004917:Erythromycin / Q000494:pharmacology*; D016908:Gram-Positive Bacterial Infections / Q000382:microbiology; D006095:Gram-Positive Cocci / Q000187:drug effects* / Q000302:isolation & purification; D006801:Humans; D008826:Microbial Sensitivity Tests; D009656:North America; D013210:Staphylococcus / Q000187:drug effects; D013291:Streptococcus / Q000187:drug effects; D014769:Virginiamycin / Q000494:pharmacology*
D000900:Anti-Bacterial Agents; C099364:RPR 106972; D014769:Virginiamycin; C062940:quinupristin-dalfopristin; D004917:Erythromycin